Open Access

Erratum to: A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy

  • Chun Hei Antonio Cheung1, 4,
  • Xueying Sun1, 2,
  • Jagat R Kanwar1, 5,
  • Ji-Zhong Bai1,
  • LiTing Cheng3 and
  • Geoffrey W Krissansen1Email author
Cancer Cell International201010:43

https://doi.org/10.1186/1475-2867-10-43

Received: 20 October 2010

Accepted: 28 October 2010

Published: 28 October 2010

The original article was published in Cancer Cell International 2010 10:36

Correction

Since publication of our article [1], we have regrettably noticed an error. The molarities of 16, 48, 80 and 112 μg/mL solutions of dNSurR9-C84A of molecular weight 42 kDa were incorrectly given as 1, 3, 5, and 7 μM. The correct molarities which should be used throughout are 0.38, 1.1, 1.9, and 2.7 μM, respectively.

Notes

Authors’ Affiliations

(1)
Department of Molecular Medicine & Pathology, Faculty of Medical and Health Sciences, The University of Auckland
(2)
Alternate address: The Hepatosplenic Surgery Center/Department of General Surgery, the First Clinical Medical School of Harbin Medical University
(3)
Graduate Institute of Vaccine Technology, National Pingtung University of Science and Technology
(4)
National Institute of Cancer Research, National Health Research Institutes
(5)
Laboratory of Immunology and Molecular Biomedical Research (LIMBR), Centre for Biotechnology and Interdisciplinary Biosciences (BioDeakin), Institute for Technology & Research Innovation (ITRI), Deakin University, Geelong, Technology Precinct (GTP)

References

  1. Cheung Hei Antonio Chun, Sun Xueying, Kanwar Jagat, Bai Ji-Zhong, Cheng LiTing, Krissansen Geoffrey: A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy. Cancer Cell International. 2010, 10: 36-10.1186/1475-2867-10-36.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Cheung et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement